Background. Many antimicrobial stewardship programs have set goals to reduce the use of fluoroquinolones because of risks of causing C. difficile and other adverse safety events. The US Food and Drug Administration issued a black box label warning for fluoroquinolones in June 2016 recommending avoidance of this class for treatment of uncomplicated infections.
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Disclosures. All authors: No reported disclosures. Background. Up to 40% of inpatients started on antibiotics for suspected infection have negative cultures from all tested body sites. The optimal duration of treatment for these patients is unknown.
Impact of Early Discontinuation of Antimicrobial Therapy on Survival in
Methods. Adults admitted to 111 hospitals between 2009 and 2015 with clinically suspected serious infection but negative cultures were identified. We deemed patients to have clinically suspected serious infection if blood cultures were drawn on hospital day 1 or 2 and IV or PO antibiotics were initiated on the day of or after blood culture draw and continued for ≥3 days. We compared outcomes for patients treated with 3-4 vs. ≥5 days of antibiotics. We excluded patients on vasopressors beyond day 2. We calculated odds ratios for in-hospital mortality (including discharge to hospice), C. difficile infection (CDI), subsequent sepsis, and antibiotic restarts >1 day after discontinuation using logistic regression, adjusting for age, race, Sequential Organ Failure Assessment (SOFA) score, and several co-morbidities; findings were confirmed by determining the average treatment effect on the treated (ATET) using propensity matching.
Results. We identified 179,421 patients with clinically suspected serious infection. Of these, 71,786 (40%) had all negative cultures; 26,437 (37%) were treated with 3-4 days of antibiotics; and 45,349 (63%) were treated with ≥5 days. Patients treated with shorter courses were younger, had lower SOFA scores, and were less likely to have concomitant sepsis. There was no difference in mortality for short vs. long course treatment (4.7% vs. 6.5%, aOR 1. Conclusion. We found no difference in mortality for patients with culture-negative clinically suspected serious infection treated with 3-4 days vs. ≥5 days. Patients treated with short courses had less CDI and sepsis after discontinuation of antibiotics but higher rates of antibiotic restarts. A randomized, controlled trial is warranted to confirm or refute these findings.
Disclosures. R. Laxminarayan, Merck: Board Member, Educational grant. Background. Telehealth offers the possibility of supporting antibiotic stewardship in settings with limited access to people with infectious diseases (ID) expertise. Previously, we described preliminary results from a pilot project that used the Veterans Affairs (VA) telehealth system to facilitate a Videoconference Antimicrobial Stewardship Team (VAST) which connected a multidisciplinary team from a rural VA medical center (VAMC) with ID physicians at a remote site to support antibiotic stewardship. Here, we present 3 distinct metrics to assess the influence of the VAST on antibiotic use at 2 intervention sites.
A Tele-Antibiotic Stewardship Program Influences Antibiotic Use at 2 Rural Veterans Affairs Medical Centers
Methods. Outcomes assessed antibiotic use in the hospital and long-term care units of 2 rural VAMCs in the year before and after VAST implementation, allowing for a 1-month wash-in period in the first month of the VAST. Using VA databases, we determined 3 metrics: the rate of antibiotic use (days of therapy per 1,000 bed days of care); the mean length of therapy (days); and the mean patient antibiotic spectrum index (ASI), a measure of antibiotic spectrum increasing from narrow to broad. Using segmented regression on monthly measures of each metric with a knot at the wash-in month (gray square), we calculated predicted values (solid lines), and confidence intervals (dashed lines) to examine trends before (black squares) and after (white squares) implementing the VAST.
Results. The rate of antibiotic use, mean length of therapy, and ASI decreased at Site A. As indicated in the figure, the effect was more pronounced in long-term care compared with the hospital, where the VAST sustained but did not accelerate downward trends. At Site B, the most notable influence of the VAST was on the ASI for the hospital and long-term care units.
Conclusion. The VAST is a feasible, sustainable program that is effective at inducing change in antibiotic use at 2 VAMCs. The influence of the VAST differed between the 2 sites and, at Site A had a more pronounced effect on the long-term care compared with hospital units. These distinct metrics capture changes in overall antibiotic use, length of therapy, and agent selection. Tele-antibiotic stewardship programs hold potential to improve antibiotic use at facilities with limited access to people with antibiotic stewardship expertise.
